Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Performance fell short of expectations due to a multiyear trend of declining veterinary clinic visits and pet owners becoming more selective in spending as price increases outpaced inflation.
Management observed a shift in the nature of competition where new entrants are using high levels of discounting, rebates, and cross-portfolio bundling to capture existing patients rather than expanding the market.
U.S. revenue declined 7%, while the U.S. Companion Animal sub-segment declined 11%., driven by significant pressure in Dermatology and parasiticides where competitive intensity and affordability concerns were most pronounced.
Livestock delivered strong 11% growth, providing a critical hedge against Companion Animal weakness, though some drivers like New World screwworm demand are considered transitory.
The company is responding with 'gross-to-net' investments—targeted promotions and rebates—to protect volume and share without permanently altering long-term list prices.
Organizational changes, including the appointment of a new CFO/COO and a new President of U.S. Commercial Operations, are designed to accelerate decision-making and execution agility.
Diagnostics remains a strategic catalyst, growing 12% as clinic revenue shifts toward urgent care and the company expands into veterinary imaging interpretation via the VitalRADS acquisition.
Full-year organic operational revenue guidance was revised to a decline of 3% to 1%, reflecting the assumption that current market pressures will persist or potentially accelerate.
The low end of the guidance range accounts for a scenario where July's market weakness continues through the second half with greater share losses in key categories.
Management expects to maintain aggressive gross-to-net investments until market share and volume stabilize, prioritizing near-term defense over immediate margin expansion.
Innovation remains the primary long-term growth driver, with the anticipated U.S. approval of long-acting Cytopoint and the commercial validation of the Vetscan OmniMax platform expected by year-end.
Cost discipline initiatives, including reduced discretionary spend and compensation-related expenses, are expected to continue providing a partial offset to revenue headwinds.
Jay Saccaro will join as EVP, CFO, and COO on August 17, a new role combining finance with global manufacturing and supply to improve supply chain connectivity.
Foreign exchange headwinds are estimated to impact the top line by approximately $60 million to $65 million and the bottom line by about $30 million for the full year.